Oxandrolone is considered to be one of the most “light” anabolic steroids. Oxandrolone is able to increase strength, while the weight of the athlete can remain unchanged.
This anabolic steroid gives an increase in the quality of muscle mass and gives the muscles a quality and filled appearance, which is why most athletes use it in the preparation for the competition.
Oxandrolone is often used as a growth stimulant in the therapy of children (boys) lagging behind in physical development. A study in Italy showed that in such patients, oxandrolone is as effective as growth hormone preparations. A study by French scientists found that the substance is superior to growth hormone in the treatment of girls with Turner syndrome, one of the reasons for the delay in physical development. In obese individuals, oral administration of oxandrolone contributed to a reduction in the mass of subcutaneous fat deposits in the abdominal region more effectively than testosterone enanthate or exercise.
The action of oxandrolone is to increase the amount of growth hormone produced in each release cycle, while the drug does not change the duration of the excretory cycles or half-lives of the hormone.
Oxandrolone solo side effects:
This is the best course in terms of side effects. There are practically none. Oxandrolone is the safest anabolic steroid. Toxicity for baking is minimal. Problems with the ligaments, as in the course of stanozolol will not, the drug does not so much draws water, does not “dry”. The drug does not aromatize, so gynecomastia does not threaten.
Hypersensitivity, prostate cancer, breast cancer (in men), breast cancer (in women with hypercalcemia), hypercalcemia, severe hepatic insufficiency, nephrosis, glomerulonephritis (nephrotic stage), pregnancy. With caution. CHF, coronary atherosclerosis, myocardial infarction (including in the anamnesis), diabetes mellitus, prostatic hyperplasia, hepatic insufficiency, renal failure, lactation period (there are no data on penetration of the drug into breast milk), elderly age. Children and adolescence (risk of premature closure of epiphyseal growth zones, early puberty in boys and virilization in girls). Acceleration of epiphyseal growth of tubular bones can be observed in children both during treatment and for 6 months after its termination.